Caplin Point Laboratories Limited · NSE:CAPLIPOINT
Caplin Point Laboratories — Investor Presentation (December 2019)
19 slides from Caplin Point Laboratories's investor presentation, December 2019
Slide 1: Investor Presentation
Investor Presentation December 2019 Proving Remedies BRINGING SMILES to People CIN: L24231TN1990PLC019053 | BSE: 524742 | NSE: CAPLIPOINT | ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET ©2018, Caplin Point Laboratories Limited – All Rights Reserved.
Slide 2: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 3: Caplin Point Laboratories (CPL) at a Glance
Caplin Point Laboratories (CPL) at a Glance Covers entire spectrum of pharmaceutical 12 ANDAs filed till date with 210+ 3100+ Products formulations with 400+ products, 36 Therapeutic 6 approved and 10 more to Scientists registered Segments in 23 countries be filed by Dec 2020 in US H1 FY20 Financial
Slide 4: Transformation across the years
Transformation across the years THEN NOW Technology and research-led marketing Market-led Company Company Focused on introducing products that Launch speciality niche products that create plugged marketplace gaps new markets in varied therapy segments Revenues from mix of generics, branded Revenue f
Slide 5: Business Model
Business Model Unique geographical Strategic manufacturing Growing presence in focus base US Market In line with strategic lean One of the few Indian companies to manufacturing, Company Strengthening the US credentials by have presence in LATAM with end- manufactures 40% of products in- entering nic
Slide 6: Inflection points in Caplin’s existence
Inflection points in Caplin’s existence Caplin attracted sizable fund Caplin’s entry into Angola Caplin entered the Liquid injectable facility infusion into the sterile that turned the business Caribbean and South approved by the USFDA injectable business from around, repaid debts America Fidelity U
Slide 7: Diversified Product Portfolio
Diversified Product Portfolio Caters to entire spectrum of pharmaceutical formulations, covering various dosage forms Total of 2,850 product licenses spread Built an end to end business with focus on bottom of the pyramid across Latin America & Africa • Early adopters from Indian pharmaceutical sect
Slide 8: Robust Distribution Network & Targeted Marketing
Robust Distribution Network & Targeted Marketing Work closely with pharmacists and trade intermediaries in the regions of its presence to ensure that medicines that are prescribed are in stock just when consumers need them Scaling up the Value Curve Plant to Portal Proposed extension from product ma
Slide 9: Emerging Markets - Driving Growth and Profitability of Business
Emerging Markets - Driving Growth and Profitability of Business Overview Strategic Focus No. 1 Indian player in Central America Invested ~ Rs.400 crore in Capex and Opex in the last Increasing focus to mainland Latin American countries 5 years through internal accruals to enter the US and (Chi
Slide 10: Research & Development Capabilities
Research & Development Capabilities Overview 5 dedicated R&D setups (3 – DSIR approved and 2 under approval) with capabilities to develop safe and effective formulations. 210+ scientists working on development of varied dosage forms such as Complex Injectables, Liposomes, Microspheres, Suspensio
Slide 11: Perungudi R&D
Perungudi R&D API R&D Center Centre Research & Development Centers
Slide 12: Amaris Clinical - CRO Division of Caplin Point
Amaris Clinical - CRO Division of Caplin Point Highlights CRO division started for Captive BA/BE LCMS-MS studies of own products, for Latam, US Sciex 4500+ : 2 and China. Sciex 6500+ : 1 Cost per study reduces by around 50% UPLC - Shimadzu Project cost at INR 29cr – internally accrued.
Slide 13: “Capital Plus” partner for Caplin Steriles Ltd.
“Capital Plus” partner for Caplin Steriles Ltd. Proposed Transaction Structure Transaction Details Objective Increase R&D capabilities to include Complex Injectable and Ophthalmic products portfolio and enhance capacities at Plant. Investment Venture Eight Roads and F-Prime Capital – Fidelity to
Slide 14: Visionary Promoters & Experienced Management
Visionary Promoters & Experienced Management Mr. C.C.Paarthipan Dr. Sridhar Ganesan Mr. D.P. Mishra Dr. K.C.John Chairman Managing Director Director Director 35+ Years experience in Pharmaceutical 30+ yrs experience in spheres of 30+ yrs experience in the area of 30+ Years of experience in t
Slide 15: Key Updates
Key Updates Expansion completed at Unit-1 in Pondicherry which includes Five State of art R&D sites addition of Injectable lines established, covering entire Preparation underway CP-4 has undergone 3 US including Lyophilized Injectables spectrum of Dosage Forms to file products in China FDA and 2 EU
Slide 16: Growth Drivers
Growth Drivers CRO wing of Caplin Point completed, Digital which will Continued intervention – cover BE/BA focus deployment As on July studies for towards of healthcare 2019, 12 own products, Bottom of before scaling portal that ANDA’s filed the Pyramid, up as a would with 6 creating a commercial ge
Slide 17: Strongly Positioned to Deliver Robust Profitable Growth & Returns
Strongly Positioned to Deliver Robust Profitable Growth & Returns Significant growth in Return Ratios adds Revenue Tripled in the last 4 years Robustly growing EBITDA & PAT margins further impetus to the growth story Revenue (in Mn) 6,487 PAT Margin EBITDA Margin ROE ROCE 5,398 38% 37% 70% 71% 71% 7
Slide 18: Financial Highlights – Q2 FY20
Financial Highlights – Q2 FY20 2,000 1,000 Q2 FY20 Highlights Xxx Target to file 10 more ANDAs before Dec 2020 1,500 • Taking the tally to 20 ANDAs filed from Caplin with 6 approvals already received • Target to file 6 API DMF filings for captive use in FY 20-21 1,000 Expansion plans at CP-1,
Slide 19: For further information, please contact
For further information, please contact: Company Investor Relations contact Christensen IR Vinod Kumar Dikshita Jain +91 44 24968119 022-42150210 investors@caplinpoint.net djain@christensenir.com 524742 CAPLIPOINT CAPL.NS © 2018 Caplin Point Laboratories Limited, All Rights Reserved. “Caplin Point”
Caplin Point Laboratories — Investor Presentation (December 2019) on 6ix